Jennison Associates LLC Boosts Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Jennison Associates LLC lifted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 47.2% in the third quarter, HoldingsChannel reports. The fund owned 2,178,580 shares of the company’s stock after buying an additional 698,712 shares during the period. Jennison Associates LLC owned approximately 0.06% of Tarsus Pharmaceuticals worth $71,653,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in TARS. Quest Partners LLC purchased a new position in Tarsus Pharmaceuticals in the 2nd quarter worth $61,000. Canada Pension Plan Investment Board bought a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at about $114,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after buying an additional 1,530 shares during the period. SG Americas Securities LLC lifted its stake in shares of Tarsus Pharmaceuticals by 87.5% in the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock valued at $238,000 after acquiring an additional 3,379 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Tarsus Pharmaceuticals by 64.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after acquiring an additional 2,879 shares during the period. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 0.7 %

NASDAQ:TARS opened at $46.58 on Thursday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a twelve month low of $15.60 and a twelve month high of $52.99. The firm’s fifty day simple moving average is $38.71 and its 200 day simple moving average is $32.77.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $54.20.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.